Filing Flows › Kyntra Bio (KYNB) › Q4 2025
Kyntra Bio (KYNB) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
Kyntra Bio (KYNB) reported revenue of $1.3M for the fourth quarter 2025 (Q4 2025), -59% from a year earlier and +19% from the quarter before.
Kyntra Bio, Q4 2025: revenue $1.3M (-59% year over year), net loss $14.2M, operating cash flow −$18.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | +19% | -59% |
| Operating profit | −$13.5M | — | — |
| Net earnings | −$14.2M | -107% | — |
| Operating cash flow | −$18.3M | — | — |
What changed
Revenue was $1.3M in Q4 2025, down 59% year over year and up 19% from the previous quarter.
Operating costs exceeded revenue by $13.5M, an operating margin of -1058.1%. Total costs grew 44% against a revenue fall of 59%. The quarter ended with a net loss of $14.2M, after a profit of $200.6M the previous quarter.
Operating cash flow was −$18.3M. Non-cash charges added back $1.2M of share-based compensation. Working capital and other items used $5.3M.
Questions
What was Kyntra Bio's revenue in the fourth quarter 2025?
Kyntra Bio (KYNB) reported revenue of $1.3M for the fourth quarter 2025 (Q4 2025), -59% from a year earlier and +19% from the quarter before.
Source: Kyntra Bio 10-K on SEC EDGAR.